Saturday, August 27, 2022 11:04:06 AM
Thank you all for your kind thoughts and prayers. She did very well from her diagnosis at the end of 2011 until about 2017 and then she went into decline. Her neurologist oncologist believed it was the radiation treatment which was having a delayed impact on her. She was 66 when diagnosed. She had a 2nd total resection during March of 2019. She followed with Avastin for about 3 months but it almost killed her. I think it caused bleeding in her GI tract. She had 1 cyber knife treatment during December of 2019. She could not tolerate any further treatment after that. I would recommend New York Presbyterian for neuro oncology treatment.
Her last MRI did show a small tumor, but she most likely did not die directly from GBM. She did die indirectly due to the treatment weakening her so much. Most GBM patients don't suffer the long term effects of radiation since they don't live that long. Hopefully, DC-Vax will able to be combined with other immunotherapies to greatly improve outcomes.
I called NWBO after her GBM reoccured during 2019 to see if there was any way she could get DC Vax again. It was not possible. It was only after this time that I researched NWBO and made a small investment and added a little more after May 10th.
Her last MRI did show a small tumor, but she most likely did not die directly from GBM. She did die indirectly due to the treatment weakening her so much. Most GBM patients don't suffer the long term effects of radiation since they don't live that long. Hopefully, DC-Vax will able to be combined with other immunotherapies to greatly improve outcomes.
I called NWBO after her GBM reoccured during 2019 to see if there was any way she could get DC Vax again. It was not possible. It was only after this time that I researched NWBO and made a small investment and added a little more after May 10th.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
